Business
Harlan Waksal, M.D. resigns as Chairman of the Board of Sevion Therapeutics
Harlan Waksal, M.D. resigns as Chairman of the Board of Sevion Therapeutics.
About this update from Eloxx Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCQB:SVON), a \n biopharmaceutical company which discovers, develops and acquires \n next-generation biologics for the treatment of cancer and immunological \n diseases, today announced that Dr. Harlan Waksal, M.D. has resigned as \n Chairman of the Board of Directors of Sevion effective March 4, 2016, \n due to the increased responsibilities and workload that comes with Dr. \n Waksal’s role as President and Chief Executive Officer at Kadmon \n Corporation, LLC. “We greatly appreciate Dr. Waksal’s presence and \n strong leadership during his tenure on the board and we wish him well in \n his business pursuits,” noted Chief Executive Officer David Rector.\n \n \n About Sevion Therapeutics\n \n \n Sevion Therapeutics is a biopharmaceutical company building and \n developing a portfolio of innovative therapeutics, from both internal \n discovery and acquisition, for the treatment of cancer and immunological \n diseases. The Company’s product candidates are derived from multiple key \n proprietary technology platforms: cell-based arrayed antibody discovery, \n ultralong antibody scaffolds and Chimerasome nanocages. Sevion has \n leveraged these technologies to build a pipeline of innovative product \n candidates. For more information, please visit SevionTherapeutics.com.\n \n \n Forward-Looking Statements\n \n \n Certain statements included in this press release are forward-looking \n statements within the meaning of the Private Securities Litigation \n Reform Act of 1995. Actual results could differ materially from such \n statements expressed or implied herein as a result of a variety of \n factors, including, but not limited to: the Company’s ability to \n continue as a going concern; the ability of the Company to consummate \n additional financings; the development of the Company’s gene and \n antibody technology; the approval of the Company’s patent applications; \n the Company’s ability to successfully defend its intellectual property \n or obtain the necessary licenses at a cost acceptable to the Company, if \n at all; the successful implementation of the Company’s research and \n development programs and collaborations; the success of the Company's \n license agreements; the accepta...